Zouras Stamatios, Stephens Jeffrey W, Abburu Srinivasa Rao, Emelle Chika
Endocrinology and Diabetes Department, Morriston Hospital, Swansea, UK.
College of Medicine, Swansea University, Swansea, UK.
BMJ Case Rep. 2017 Nov 4;2017:bcr-2017-221089. doi: 10.1136/bcr-2017-221089.
Anti-leucine-richglioma inactivated protein 1 (LGI1) encephalitis has an autoimmune origin and can be reversed with immunotherapy. It is obvious that identifying and treating this condition early is of paramount importance. We present the case of a 69-year-old man who was admitted to hospital with faciobrachial dystonic seizures and was found to have antibodies to LGI1. His symptoms started approximately 3 months prior admission to the hospital. There had also been some subtle cognitive impairment. He was treated with two courses of intravenous immunoglobulin and commenced on prednisolone 50 mg daily and clonazepam 500 µg at night. Despite these treatments, his seizures were becoming progressively more frequent and severe. He then underwent treatment with a course of plasma exchange followed by an intravenous infusion of methylprednisolone and returned to his previous baseline function.
抗富含亮氨酸胶质瘤失活蛋白1(LGI1)脑炎具有自身免疫起源,可通过免疫治疗逆转。显然,早期识别和治疗这种疾病至关重要。我们报告一例69岁男性病例,该患者因面臂肌张力障碍性癫痫入院,发现其体内存在抗LGI1抗体。他的症状在入院前约3个月开始出现。同时还存在一些轻微的认知障碍。他接受了两个疗程的静脉注射免疫球蛋白治疗,并开始每日服用50毫克泼尼松龙和每晚服用500微克氯硝西泮。尽管进行了这些治疗,他的癫痫发作却越来越频繁且严重。随后,他接受了一个疗程的血浆置换治疗,接着静脉输注甲泼尼龙,之后恢复到了之前的基线功能状态。